Science Translational Medicine Publishes First-in-Human Clinical Data and Supporting Preclinical Data for SYNB1020, Synlogic’s Synthetic Biotic™ Medicine in Development as a Potential Trea...
Synlogic, Inc. (SYBX)
Last synlogic, inc. earnings: 3/12 04:19 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investor.synlogictx.com/news-and-events/news-releases
Company Research
Source: Business Wire
–Phase 1 clinical trial to evaluate safety and tolerability of SYNB1020 in healthy volunteers demonstrated safety, clearance and proof of mechanism– – Data from ongoing Phase 1b/2a clinical trial in patients with cirrhosis and elevated ammonia expected mid-2019 – CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Synlogic, Inc., (Nasdaq: SYBX) a clinical stage company applying synthetic biology to beneficial microbes to develop novel, living medicines, today announced the publication in Science Translational Medicine of clinical data from its Phase 1 clinical study in healthy volunteers and supporting preclinical data from its investigational Synthetic Biotic candidate, SYNB1020. The data support the continued development of SYNB1020 which is currently being evaluated in a Phase 1b/2a clinical trial in patients with cirrhosis and elevated blood ammonia. “These data demonstrate that we can engi
Show less
Read more
Impact Snapshot
Event Time:
SYBX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
---|---|---|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
Last Price | ||
VWAP | ||
High:
|
Max Up |
High:
|
Low:
|
Max Down |
Low:
|
%
|
Post news range |
%
|
|
Price change |
|
|
Price Change Percentage |
|
|
S&P 500 (SPX) |
|
%
|
Volume ratio |
%
|
Volume | ||
Ticks | ||
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
SYBX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
SYBX alerts
High impacting Synlogic, Inc. news events
Weekly update
A roundup of the hottest topics
SYBX
News
- Synlogic, Inc. (NASDAQ: SYBX) was upgraded by analysts at HC Wainwright from a "sell" rating to a "neutral" rating.MarketBeat
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial Results [Yahoo! Finance]Yahoo! Finance
- Synlogic Reports Fourth Quarter and Full Year 2023 Financial ResultsGlobeNewswire
- Synlogic Adopts Limited Duration Stockholders Rights Plan [Yahoo! Finance]Yahoo! Finance
- Synlogic Adopts Limited Duration Stockholders Rights PlanGlobeNewswire
SYBX
Earnings
- 11/9/23 - Miss
SYBX
Sec Filings
- 3/21/24 - Form 3
- 3/21/24 - Form 4
- 3/21/24 - Form 3
- SYBX's page on the SEC website